Barriers to Effective Postmenopausal Osteoporosis Treatment: A Qualitative Study of Patients’ and Practitioners’ Views

Background Only a minority of patients at high risk for osteoporotic fracture receive treatment. Objective Study patients’ and physicians’ views regarding postmenopausal osteoporosis (PMO) to identify impediments to good care. Methods A qualitative study involving 18 physicians and 37 women (age 57–87) with PMO. Results All women interviewed considered PMO to be somewhat normal wear-and-tear associated with old age. The women identified a large number of "causes" for osteoporosis but finally viewed it as chance. They all described its progression as slow. Three representations of PMO severity were identified: some women tended to interpreted it as benign (21), others tended to dramatize it (11), and the rest were uncertain (5). These representations did not appear linked to age or fracture. Even the women who associated fracture and PMO were uncertain of the link between them. Fractures were considered to be random events, independent of osteoporosis. Women received general life-style recommendations from their physicians positively, but did not connect them specifically to osteoporosis. Indeed, these recommendations, along with the fear of side effects, the absence of tangible results of treatments, the view of PMO as a natural process, and the representations of PMO severity are factors that may deter treatments and impact compliance. As for the physicians, they identified eight risk factors, recognizing menopause as central to PMO and recognized the link between risk of fracture and PMO. However, some considered the impact of fractures to be limited in time, and viewed PMO as a "benign" disease. Seeing the progression of PMO as slow and inevitable reduced their urgency to diagnose and treat it as compared to other diseases. Some physicians acknowledged limited mastery of the existing therapeutic arsenal and unsuccessful handling of patient compliance. Conclusion Women’s and physicians’ perspectives on PMO converged to trivialize postmenopausal osteoporosis and thus disqualify it as a legitimate disease. A better understanding of women’s and physicians’ views, practices, and concerns related to PMO can improve osteoporosis management.

[1]  S. Cummings,et al.  Vertebral Fractures and Mortality in Older Women , 2017 .

[2]  D. Marinac-Dabic,et al.  National and international postmarket research and surveillance implementation: achievements of the International Consortium of Orthopaedic Registries initiative. , 2014, The Journal of bone and joint surgery. American volume.

[3]  E. Duncan,et al.  Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy , 2014, Pharmacoepidemiology and drug safety.

[4]  D. Solomon,et al.  Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011 , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[6]  D. Beaton,et al.  Patient perceptions of provider barriers to post-fracture secondary prevention , 2014, Osteoporosis International.

[7]  Daniala L. Weir,et al.  Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials , 2014, Osteoporosis International.

[8]  D. Dirschl,et al.  Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. , 2014, The Journal of bone and joint surgery. American volume.

[9]  D. Beaton,et al.  Understanding osteoporosis and fractures: an introduction to the use of qualitative research , 2014, Archives of Orthopaedic and Trauma Surgery.

[10]  D. Wysowski,et al.  Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. , 2013, Bone.

[11]  J. Eisman,et al.  Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  C. Cooper,et al.  Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.

[13]  D. Beaton,et al.  Non-pharmacological strategies used by patients at high risk for future fracture to manage fracture risk—a qualitative study , 2013, Osteoporosis International.

[14]  S. Oliver,et al.  Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ , 2012, BMC Medical Research Methodology.

[15]  D. Beaton,et al.  Patients reject the concept of fragility fracture—a new understanding based on fracture patients’ communication , 2012, Osteoporosis International.

[16]  L. Lix,et al.  A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving , 2012, Osteoporosis International.

[17]  K. Michaëlsson,et al.  Bisphosphonate use and atypical fractures of the femoral shaft. , 2011, The New England journal of medicine.

[18]  G. Ioannidis,et al.  Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study , 2011, Osteoporosis International.

[19]  L. March,et al.  Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality , 2010, The Medical journal of Australia.

[20]  Sei J. Lee,et al.  Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture , 2010, Journal of the American Geriatrics Society.

[21]  A. LaCroix,et al.  Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) , 2010, Osteoporosis International.

[22]  Cathleen S. Colón-Emeric,et al.  Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men , 2010, Annals of Internal Medicine.

[23]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[24]  C. Roux Osteopenia: is it a problem? , 2009 .

[25]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[26]  G. Dinant,et al.  Clinical subsequent fractures cluster in time after first fractures , 2008, Annals of the rheumatic diseases.

[27]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[28]  Lora Giangregorio,et al.  Do patients perceive a link between a fragility fracture and osteoporosis? , 2008, BMC musculoskeletal disorders.

[29]  P. Sainsbury,et al.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. , 2007, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[30]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[31]  Qualitative Research: Understanding Patients' Needs and Experiences , 2007, PLoS medicine.

[32]  S. Boonen,et al.  Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. , 2007, The New England journal of medicine.

[33]  L. Meadows,et al.  The importance of communication in secondary fragility fracture treatment and prevention , 2007, Osteoporosis International.

[34]  L. Giangregorio,et al.  Fragility fractures and the osteoporosis care gap: an international phenomenon. , 2006, Seminars in arthritis and rheumatism.

[35]  P. Salkovskis,et al.  Prediction of psychological reactions to bone density screening for osteoporosis using a cognitive-behavioral model of health anxiety. , 2002, Behaviour research and therapy.

[36]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[37]  Rosaline S Barbour,et al.  Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? , 2001, BMJ : British Medical Journal.

[38]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[39]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  C. Pope,et al.  Assessing quality in qualitative research , 2000, BMJ : British Medical Journal.

[41]  H K Genant,et al.  Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. , 1999, Archives of internal medicine.

[42]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[43]  K. A. McKibbon,et al.  Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications , 1996, The Lancet.

[44]  J. Kitzinger,et al.  Qualitative Research: Introducing focus groups , 1995 .

[45]  N Mays,et al.  Qualitative Research: Rigour and qualitative research , 1995 .

[46]  C. Brodsky The Discovery of Grounded Theory: Strategies for Qualitative Research , 1968 .

[47]  A. Strauss,et al.  The discovery of grounded theory: strategies for qualitative research aldine de gruyter , 1968 .